7 research outputs found
Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism
Synaptic impairment might precede neuronal degeneration in Parkinsonâs disease. However, the intimate mechanisms
altering synaptic function by the accumulation of presynaptic α-synuclein in striatal dopaminergic terminals before
dopaminergic death occurs, have not been elucidated. Our aim is to unravel the sequence of synaptic functional and
structural changes preceding symptomatic dopaminergic cell death. As such, we evaluated the temporal sequence
of functional and structural changes at striatal synapses before parkinsonian motor features appear in a rat model of
progressive dopaminergic death induced by overexpression of the human mutated A53T α-synuclein in the substantia
nigra pars compacta, a protein transported to these synapses. Sequential window acquisition of all theoretical mass
spectra proteomics identified deregulated proteins involved first in energy metabolism and later, in vesicle cycling
and autophagy. After protein deregulation and when α-synuclein accumulated at striatal synapses, alterations to mitochondrial bioenergetics were observed using a Seahorse XF96 analyser. Sustained dysfunctional mitochondrial bioenergetics was followed by a decrease in the number of dopaminergic terminals, morphological and ultrastructural
alterations, and an abnormal accumulation of autophagic/endocytic vesicles inside the remaining dopaminergic fibres
was evident by electron microscopy. The total mitochondrial population remained unchanged whereas the number of
ultrastructurally damaged mitochondria increases as the pathological process evolved. We also observed ultrastructural signs of plasticity within glutamatergic synapses before the expression of motor abnormalities, such as a reduction in
axospinous synapses and an increase in perforated postsynaptic densities. Overall, we found that a synaptic energetic
failure and accumulation of dysfunctional organelles occur sequentially at the dopaminergic terminals as the earliest
events preceding structural changes and cell death. We also identify key proteins involved in these earliest functional
abnormalities that may be modulated and serve as therapeutic targets to counterbalance the degeneration of dopaminergic cells to delay or prevent the development of Parkinsonâs disease.This study was funded by the Instituto de Salud Carlos III through the projects PI14/00763 and PI19/01915 (co-funded by ERDF/ESF, âInvesting in your futureâ). L.M.-G. held a Predoctoral Research Fellowship from the University of the Basque Country (UPV/EHU). T.R.-C. and A.Q.-V. were funded by CIBERNED. T.R.-C. held a FundaciĂłn JesĂșs de Gangoiti Barrera Foundation grant (Bilbao, Spain). H.J.-U. and A.B.-I. held a Predoctoral Research Fellowship from the Government of the Basque Country. Israel Science Foundation (536/19) and the Spanish Ministry of Science (SAF2016-78071-R) funded the contribution of S.K. and A.O
Synaptic alterations in the hippocampus of an animal model of progressive parkinsonism and the effect of dopaminergic treatments
El capĂtulo 3 estĂĄ sujeto a confidencialidad por la autora.
223 p.This Ph.D. project is focused on the characterization of pathological events in the hippocampus, which could be related to non-motor manifestation in Parkinson's disease such as behavioral and memory impairments. For that purpose, we have studied the temporal sequence of functional and structural changes in the hippocampus in a rat model of progressive parkinsonism induced by the overexpression of human '-synuclein (hα-syn) with the A53T mutation (AAV-hα-syn) in the substantia nigra compacta (SNpc). We observed a progressive hα-syn overexpression in the SNpc and the adjacent ventral tegmental area (VTA) associated with dopaminergic neuron degeneration in both nuclei. Moreover, hα-syn was also expressed in the glutamatergic neurons of the VTA, which together with the dopaminergic neurons, project to the hippocampus modulating hippocampal function and memory processes. In the hippocampus, we observed a progressive hα-syn expression within the different afferent pathways from the VTA (dopaminergic, glutamatergic and GABAergic pathways) since the earliest stages after theAAV-h¿-syn inoculation. Furthermore, AAV-hα-syn inoculated animals showed a trend towards decreased performance in a hippocampal-dependent memory task, which was concomitant to the onset of nigral dopaminergic degeneration and motor impairment. Interestingly, long-term potentiation (LTP), the cellular mechanism for memory storage, was already impaired in the hippocampal synapse since the beginning of hα-syn expression, probably through increasing basal synaptic transmission. The dopaminergic agonist pramipexole (PPX) and the dopamine precursor L-DOPA restored hippocampal LTP in the AAV-hα-syn animals, although the latter was only effective at the latest time point evaluated. This might be explained by the compromised intracellular transport and synaptic vesicle trafficking observed by using a proteomics approach and suggesting a deficient neurotransmitter release at the earliest time points after the AAV-hα-syn inoculation. By contrast, at the latest time point after the AAV-hα-syn inoculation, deregulated proteins in isolated hippocampal synapses are involved in homeostatic processes such as the regulation of calcium levels, membrane potential, and receptor-mediated signaling pathways. Finally, with an in vivo PET study, we found decreased glucose metabolism in the hippocampus of animals with an established dopaminergic lesion chronically treated with PPX. Overall, we show that progressive synucleinopathy is associated with early synaptic dysfunction in the hippocampus and defective memory, providing an excellent model for the development of disease modifying new synapse-targeted therapies for Parkinson's disease
Recommended from our members
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Learning and memory mainly rely on correct synaptic function in the hippocampus and other brain regions. In Parkinsons disease, subtle cognitive deficits may even precede motor signs early in the disease. Hence, we set out to unravel the earliest hippocampal synaptic alterations associated with human α-synuclein overexpression prior to and soon after the appearance of cognitive deficits in a parkinsonism model. We bilaterally injected adeno-associated viral vectors encoding A53T-mutated human α-synuclein into the substantia nigra of rats, and evaluated them 1, 2, 4 and 16 weeks post-inoculation by immunohistochemistry and immunofluorescence to study degeneration and distribution of α-synuclein in the midbrain and hippocampus. The object location test was used to evaluate hippocampal-dependent memory. Sequential window acquisition of all theoretical mass spectrometry-based proteomics and fluorescence analysis of single-synapse long-term potentiation were used to study alterations to protein composition and plasticity in isolated hippocampal synapses. The effect of L-DOPA and pramipexole on long-term potentiation was also tested. Human α-synuclein was found within dopaminergic and glutamatergic neurons of the ventral tegmental area, and in dopaminergic, glutamatergic and GABAergic axon terminals in the hippocampus from 1 week post-inoculation, concomitant with mild dopaminergic degeneration in the ventral tegmental area. In the hippocampus, differential expression of proteins involved in synaptic vesicle cycling, neurotransmitter release and receptor trafficking, together with impaired long-term potentiation were the first events observed (1 week post-inoculation), preceding cognitive deficits (4 weeks post-inoculation). Later on, at 16 weeks post-inoculation, there was a deregulation of proteins involved in synaptic function, particularly those involved in the regulation of membrane potential, ion balance and receptor signalling. Hippocampal long-term potentiation was impaired before and soon after the onset of cognitive deficits, at 1 and 4 weeks post-inoculation, respectively. L-DOPA recovered hippocampal long-term potentiation more efficiently at 4 weeks post-inoculation than pramipexole, which partially rescued it at both time points. Overall, we found impaired synaptic plasticity and proteome dysregulation at hippocampal terminals to be the first events that contribute to the development of cognitive deficits in experimental parkinsonism. Our results not only point to dopaminergic but also to glutamatergic and GABAergic dysfunction, highlighting the relevance of the three neurotransmitter systems in the ventral tegmental area-hippocampus interaction from the earliest stages of parkinsonism. The proteins identified in the current work may constitute potential biomarkers of early synaptic damage in the hippocampus and hence, therapies targeting these could potentially restore early synaptic malfunction and consequently, cognitive deficits in Parkinsons disease
Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
In the original version of this article, the Figure 3 was published in an incorrect format, even though the data and the related information in the text are correct
Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease
International audienc
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit
Learning and memory mainly rely on correct synaptic function in the hippocampus and other brain regions. In Parkinson's disease, subtle cognitive deficits may even precede motor signs early in the disease. Hence, we set out to unravel the earliest hippocampal synaptic alterations associated with human α-synuclein overexpression prior to and soon after the appearance of cognitive deficits in a parkinsonism model. We bilaterally injected adeno-associated viral vectors encoding A53T-mutated human α-synuclein into the substantia nigra of rats, and evaluated them 1, 2, 4 and 16 weeks post-inoculation by immunohistochemistry and immunofluorescence to study degeneration and distribution of α-synuclein in the midbrain and hippocampus. The object location test was used to evaluate hippocampal-dependent memory. Sequential window acquisition of all theoretical mass spectrometry-based proteomics and fluorescence analysis of single-synapse long-term potentiation were used to study alterations to protein composition and plasticity in isolated hippocampal synapses. The effect of L-DOPA and pramipexole on long-term potentiation was also tested. Human α-synuclein was found within dopaminergic and glutamatergic neurons of the ventral tegmental area, and in dopaminergic, glutamatergic and GABAergic axon terminals in the hippocampus from 1 week post-inoculation, concomitant with mild dopaminergic degeneration in the ventral tegmental area. In the hippocampus, differential expression of proteins involved in synaptic vesicle cycling, neurotransmitter release and receptor trafficking, together with impaired long-term potentiation were the first events observed (1 week post-inoculation), preceding cognitive deficits (4 weeks post-inoculation). Later on, at 16 weeks post-inoculation, there was a deregulation of proteins involved in synaptic function, particularly those involved in the regulation of membrane potential, ion balance and receptor signalling. Hippocampal long-term potentiation was impaired before and soon after the onset of cognitive deficits, at 1 and 4 weeks post-inoculation, respectively. L-DOPA recovered hippocampal long-term potentiation more efficiently at 4 weeks post-inoculation than pramipexole, which partially rescued it at both time points. Overall, we found impaired synaptic plasticity and proteome dysregulation at hippocampal terminals to be the first events that contribute to the development of cognitive deficits in experimental parkinsonism. Our results not only point to dopaminergic but also to glutamatergic and GABAergic dysfunction, highlighting the relevance of the three neurotransmitter systems in the ventral tegmental area-hippocampus interaction from the earliest stages of parkinsonism. The proteins identified in the current work may constitute potential biomarkers of early synaptic damage in the hippocampus and hence, therapies targeting these could potentially restore early synaptic malfunction and consequently, cognitive deficits in Parkinson's disease